These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6230680)

  • 1. Effect of oral mesoglycan on plasma lipoprotein concentration and on lipoprotein lipase activity in primary hyperlipoproteinemia.
    Postiglione A; De Simone B; Rubba P; Lamenza F; Montefusco S; Mastranzo P
    Pharmacol Res Commun; 1984 Jan; 16(1):1-8. PubMed ID: 6230680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
    Sirtori M; Montanari G; Gianfranceschi G; Malacrida MG; Battistin P; Morazzoni G; Tremoli E; Colli S; Maderna P; Sirtori CR
    Atherosclerosis; 1983 Nov; 49(2):149-61. PubMed ID: 6365105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
    Lopez Rodriguez J; Martorell J
    Clin Ther; 1980; 3(4):234-41. PubMed ID: 7273061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia.
    Bradford RH; Goldberg AC; Schonfeld G; Knopp RH
    Atherosclerosis; 1992 Jan; 92(1):31-40. PubMed ID: 1575820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term effects of a glycosaminoglycan on plasma lipids].
    Avogaro P; Bittolo-Bon G; Alessandrini P
    Clin Ter; 1981 Jul; 98(1):47-61. PubMed ID: 7249572
    [No Abstract]   [Full Text] [Related]  

  • 9. On the effects of dietary n-3 fatty acids (Maxepa) on plasma lipids and lipoproteins in patients with hyperlipidaemia.
    Simons LA; Hickie JB; Balasubramaniam S
    Atherosclerosis; 1985 Jan; 54(1):75-88. PubMed ID: 3888229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma lipoprotein levels and the prevalence of hyperlipoproteinemia in a Canadian working population.
    Jones GJ; Hewitt D; Godin GJ; Breckenridge WC; Bird J; Mishkel MA; Steiner G; Little JA
    Can Med Assoc J; 1980 Jan; 122(1):37-8, 40-6. PubMed ID: 7363194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV].
    Bednarska-Makaruk M; Kuźmińska A; Chotkowska E; Kurjata P; Polakowska M; Broda G; Rywik S
    Pol Arch Med Wewn; 1992 Mar; 87(3):149-56. PubMed ID: 1523145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
    Artery; 1985; 12(6):363-81. PubMed ID: 4051756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
    Gavish D; Oschry Y; Fainaru M; Eisenberg S
    Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
    Vessby B; Lithell H; Ledermann H
    Atherosclerosis; 1982 Jul; 44(1):113-8. PubMed ID: 7115473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. A placebo-controlled trial.
    Harris WS; Dujovne CA; Zucker M; Johnson B
    Ann Intern Med; 1988 Sep; 109(6):465-70. PubMed ID: 3166357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
    Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.